Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin Y-like protein 2 (CCNYL2) is annotated as a pseudogene and is predicted to enable protein kinase binding activity and potentially participate in the regulation of canonical Wnt signaling pathways[4][2]. Currently, there is no confirmed evidence that CCNYL2 encodes a functional protein in humans, nor is there evidence supporting its role as a therapeutic target, disease biomarker, or drug interaction partner. The gene is part of the cyclins (CCN) family, but is generally classified as a pseudogene with limited functional characterization and uncertain biological roles[4][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclin Y-like protein 2 (pseudogene) (CCNYL2).